This company listing is no longer active
Laboratorio Reig Jofre Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 1/6
Laboratorio Reig Jofre's earnings have been declining at an average annual rate of -7.8%, while the Pharmaceuticals industry saw earnings growing at 13.8% annually. Revenues have been growing at an average rate of 9.1% per year. Laboratorio Reig Jofre's return on equity is 2.7%, and it has net margins of 2.1%.
Wichtige Informationen
-7.8%
Wachstumsrate der Gewinne
-14.2%
EPS-Wachstumsrate
| Pharmaceuticals Wachstum der Industrie | 5.0% |
| Wachstumsrate der Einnahmen | 9.1% |
| Eigenkapitalrendite | 2.7% |
| Netto-Marge | 2.1% |
| Nächste Ertragsaktualisierung | 26 Jul 2022 |
Jüngste Aktualisierungen vergangener Leistungen
Keine Aktualisierungen
Recent updates
Keine Aktualisierungen
Aufschlüsselung der Einnahmen und Ausgaben
Wie Laboratorio Reig Jofre Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 31 Dec 21 | 240 | 5 | 74 | 0 |
| 30 Sep 21 | 237 | 6 | 77 | 0 |
| 30 Jun 21 | 234 | 6 | 76 | 0 |
| 31 Mar 21 | 234 | 6 | 76 | 0 |
| 31 Dec 20 | 234 | 6 | 76 | 0 |
| 30 Sep 20 | 229 | 8 | 75 | 0 |
| 30 Jun 20 | 229 | 6 | 72 | 0 |
| 31 Mar 20 | 219 | 6 | 70 | 0 |
| 31 Dec 19 | 206 | 5 | 68 | 0 |
| 30 Sep 19 | 199 | 7 | 68 | 0 |
| 30 Jun 19 | 188 | 9 | 67 | 0 |
| 31 Mar 19 | 188 | 9 | 66 | 0 |
| 31 Dec 18 | 185 | 9 | 65 | 0 |
| 30 Sep 18 | 185 | 10 | 60 | 0 |
| 30 Jun 18 | 179 | 9 | 59 | 0 |
| 31 Mar 18 | 175 | 9 | 58 | 0 |
| 31 Dec 17 | 172 | 9 | 58 | 0 |
| 30 Sep 17 | 164 | 5 | 58 | 0 |
| 30 Jun 17 | 164 | 7 | 57 | 0 |
| 31 Mar 17 | 164 | 8 | 57 | 0 |
| 31 Dec 16 | 161 | 8 | 55 | 0 |
| 30 Sep 16 | 160 | 5 | 55 | 0 |
| 30 Jun 16 | 159 | 5 | 54 | 0 |
| 31 Mar 16 | 156 | 5 | 53 | 1 |
| 31 Dec 15 | 157 | 9 | 53 | 0 |
Qualität der Erträge: RJF.D has high quality earnings.
Wachsende Gewinnspanne: RJF.D's current net profit margins (2.1%) are lower than last year (2.4%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: RJF.D's earnings have declined by 7.8% per year over the past 5 years.
Beschleunigtes Wachstum: RJF.D's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Erträge im Vergleich zur Industrie: RJF.D had negative earnings growth (-10.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (8.9%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: RJF.D's Return on Equity (2.7%) is considered low.